{
    "clinical_study": {
        "@rank": "30262", 
        "arm_group": {
            "arm_group_label": "ASP015K and verapamil", 
            "arm_group_type": "Experimental", 
            "description": "Single dose of ASP015K, then repeat dose of  verapamil, then a second single dose of ASP015K while continuing verapamil"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the effect of verapamil, a P-glycoprotein (P-gp)\n      inhibitor, on the pharmacokinetics of ASP015K.  This study will also assess the safety and\n      tolerability of ASP015K administered alone and also and in combination with verapamil."
        }, 
        "brief_title": "A Study to Evaluate the Effect of Verapamil on the Pharmacokinetics of ASP015K in Healthy Adult Subjects", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Healthy Subjects", 
            "Pharmacokinetics of ASP015K"
        ], 
        "detailed_description": {
            "textblock": "Eligible subjects will be admitted to the clinical unit on day -1 and remain confined until\n      day 15."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject has a Body Mass Index (BMI) range of 18.5-32.0 kg/m2, inclusive, and must\n             weigh at least 50 kg\n\n          -  Subject must be capable of swallowing multiple tablets\n\n          -  Subject agrees not to participate in another investigational study while on treatment\n\n        Exclusion Criteria:\n\n          -  Subject has a known or suspected hypersensitivity to verapamil, ASP015K, or any\n             components of the formulations used.\n\n          -  Subject has any of the liver function tests above the upper limit of normal (ULN)\n\n          -  Subject has any clinically significant history of allergic conditions (including drug\n             allergies, asthma, eczema or anaphylactic reactions, but excluding untreated,\n             asymptomatic, seasonal allergies at time of dosing)\n\n          -  Subject has any history or evidence of any clinically significant cardiovascular, GI,\n             endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary,\n             neurologic, dermatologic, psychiatric, renal, and/or other major disease or\n             malignancy\n\n          -  Subject has/had febrile illness or symptomatic, viral, bacterial (including upper\n             respiratory) infection, or fungal (noncutaneous) infection within 1 week prior to day\n             -1.\n\n          -  Subject has any clinically significant abnormality following physical examination,\n             ECG, such as sick sinus syndrome, second- or third-degree atrioventricular block, or\n             atrial flutter/atrial fibrillation, or clinical laboratory tests\n\n          -  Subject has a mean pulse < 50 or > 90 beats per minute (bpm); mean systolic blood\n             pressure (SBP) < 100 or > 140 mmHg; mean diastolic blood pressure (DBP) < 60 or > 90\n             mmHg (measurements taken in triplicate after subject has been resting in sitting\n             position for 5 minutes)\n\n          -  Subject has a mean QTcF interval of > 430 msec (for males) and > 450 msec (for\n             females)\n\n          -  Subject has used any prescribed or nonprescribed drugs (including vitamins, natural\n             and herbal remedies, e.g., St. John's Wort) in the 2 weeks prior to study drug\n             administration, with the exception of hormone replacement therapy (HRT) and\n             intermittent acetaminophen (no more than 2 g per day)\n\n          -  Subject has smoked or has used tobacco-containing products and nicotine or\n             nicotine-containing products in the past 6 months\n\n          -  Subject has a history of consuming more than 14 units of alcoholic beverages per week\n             within 6 months prior to screening or has a history of alcoholism or drug/chemical\n             substance abuse within past 2 years prior to screening (Note: one unit = 12 ounces of\n             beer, 4 ounces of wine or 1 ounce of spirits)\n\n          -  Subject has a positive test for alcohol, drugs of abuse, or cotinine\n\n          -  Subject anticipates an inability to abstain from xanthine (e.g., caffeine),\n             grapefruit, Seville oranges (including marmalade), star fruit, or any products\n             containing these items from 72 hours prior to day -1 and throughout the duration of\n             the study\n\n          -  Subject has used any inducer of metabolism (e.g., barbiturates, rifampin) in the past\n             3 months prior to day -1\n\n          -  Subject has had any significant blood loss, donated 1 unit (450 mL) of blood or more,\n             or received a transfusion of any blood or blood products within 60 days or donated\n             plasma within past 7 days\n\n          -  Subject has a positive test for hepatitis B surface antigen (HBsAg), anti-hepatitis A\n             virus (Immunoglobulin [Ig] M), anti-hepatitis C virus (HCV), hepatitis B core\n             antibody or anti-human immunodeficiency virus (HIV) type 1 or type 2\n\n          -  Subject has a positive tuberculosis (TB) skin test, Quantiferon Gold\u00ae test or T-SPOT\u00ae\n             test\n\n          -  Subject received any vaccine within 60 days prior to study drug administration\n\n          -  Subject has an absolute neutrophil count (ANC) < 2000 cells/mm3 or a creatine\n             phosphokinase (CPK) > 1.5 x ULN\n\n          -  Subject has had major gastrointestinal (GI) surgery or has a medical condition, which\n             may inhibit the absorption and/or metabolism of study drug\n\n          -  Subject has participated in any interventional clinical study or has been treated\n             with any investigational drugs within 30 days or 5 half-lives of the drug, whichever\n             is longer"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 4, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02111317", 
            "org_study_id": "015K-CL-PK04"
        }, 
        "intervention": [
            {
                "arm_group_label": "ASP015K and verapamil", 
                "description": "oral", 
                "intervention_name": "ASP015K", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "ASP015K and verapamil", 
                "description": "oral", 
                "intervention_name": "verapamil", 
                "intervention_type": "Drug", 
                "other_name": "CALAN\u00ae"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Verapamil"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "ASP015K", 
            "Pharmacokinetics", 
            "Healthy Subjects"
        ], 
        "lastchanged_date": "April 7, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Glendale", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "91206"
                }, 
                "name": "PAREXEL"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1, Open-label, Single-Sequence, Crossover Drug Interaction Study to Evaluate the Effect of Verapamil on the Pharmacokinetics of ASP015K in Healthy Adult Subjects", 
        "overall_official": {
            "affiliation": "Astellas Pharma Global Development, Inc.", 
            "last_name": "Global Clinical Pharmacology Lead", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Pharmacokinetics of ASP015K: Maximum concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Days 1-4 and Days 12-15"
            }, 
            {
                "measure": "Pharmacokinetics of ASP015K: Area under the concentration-time curve (AUC) from time of dosing to the last quantifiable concentration (AUClast)", 
                "safety_issue": "No", 
                "time_frame": "Days 1-4 and Days 12-15"
            }, 
            {
                "measure": "Pharmacokinetics of ASP015K: AUC from the time of dosing extrapolated to time infinity (AUCinf)", 
                "safety_issue": "No", 
                "time_frame": "Days 1-4 and Days 12-15"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02111317"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacokinetic profile of ASP015K:  time of maximum plasma concentration (tmax), terminal elimination half-life (t\u00bd), apparent total systemic clearance (CL/F), and apparent volume of distribution during the terminal elimination phase (Vz/F)", 
                "safety_issue": "No", 
                "time_frame": "Days 1-4 and Days 12-15"
            }, 
            {
                "measure": "Pharmacokinetic profile of ASP015K metabolites:  Cmax, AUClast, AUCinf, tmax and t\u00bd", 
                "safety_issue": "No", 
                "time_frame": "Days 1-4 and Days 12-15"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "collaborator": {
                "agency": "Janssen Biotech, Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Astellas Pharma Global Development, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}